Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Immunocore Holdings (IMCR) Operating Margin (2023 - 2025)

Immunocore Holdings (IMCR) has disclosed Operating Margin for 3 consecutive years, with 18.85% as the latest value for Q4 2025.

  • Quarterly Operating Margin rose 430.0% to 18.85% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 11.34% through Dec 2025, up 1138.0% year-over-year, with the annual reading at 11.34% for FY2025, 1138.0% up from the prior year.
  • Operating Margin hit 18.85% in Q4 2025 for Immunocore Holdings, down from 6.92% in the prior quarter.
  • In the past five years, Operating Margin ranged from a high of 3.85% in Q1 2025 to a low of 37.57% in Q1 2024.
  • Historically, Operating Margin has averaged 19.45% across 3 years, with a median of 21.53% in 2023.
  • Biggest five-year swings in Operating Margin: crashed -1069bps in 2024 and later soared 3372bps in 2025.
  • Year by year, Operating Margin stood at 24.3% in 2023, then increased by 5bps to 23.14% in 2024, then rose by 19bps to 18.85% in 2025.
  • Business Quant data shows Operating Margin for IMCR at 18.85% in Q4 2025, 6.92% in Q3 2025, and 15.18% in Q2 2025.